ロード中...
Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation
Aim: The selective BRAF and MEK inhibitors (BRAFi+MEKi) have substantially improved the survival of melanoma patients with BRAF V600 mutations. However, BRAFi+MEKi can also cause severe or fatal outcomes. We aimed to identify and compare serious adverse events (sAEs) that are significantly associate...
保存先:
| 出版年: | Cancers (Basel) |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7352287/ https://ncbi.nlm.nih.gov/pubmed/32580351 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12061650 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|